Here's Why Drugmakers Face a Dilemma Now That 2 Vaccines Are Rolling Out
The authorization of two coronavirus vaccines by the Food and Drug Administration makes it more complicated for other drug companies to get their vaccines through the clinical trial process. In this video from Motley Fool Live, recorded on Dec. 21, Corinne Cardina, bureau chief of healthcare and cannabis, and Fool.com contributor Brian Orelli discuss how AstraZeneca (NASDAQ: AZN) is dealing with participants in its study who might want to get the already-authorized vaccines. They also discuss the ramifications of the authorizations on clinical trial enrollment for companies that still need to run their phase 3 studies, such as Novavax (NASDAQ: NVAX) and Inovio (NASDAQ: INO).
Source Fool.com
